MedTrace Logo

A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

NCT01089738 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-11-06

No results posted yet for this study

Summary

This study is designed to look at the safety and blood concentrations of PF-03382792 in healthy elderly subjects after taking multiple doses for 14 days.

Conditions

  • Healthy

Interventions

DRUG

PF-03382792 0.5mg

0.5 mg PF-03382792, qd, for 14 days or placebo

DRUG

PF-03382792 1.5 mg

1.5 mg PF-03382792, qd, for 14 days or placebo

DRUG

PF-03382792 5 mg

5 mg PF-03382792, qd, for 14 days or placebo

DRUG

PF-03382792 15 mg

15 mg PF-03382792, qd, for 14 days or placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
65 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-01
Primary Completion
2011-04-25
Completion
2011-04-25

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01089738 on ClinicalTrials.gov